-+ 0.00%
-+ 0.00%
-+ 0.00%
Abera Bioscience Secures All Approvals for Ab-01.12 Phase 1 Trial
Share
Listen to the news
Abera Bioscience Secures All Approvals for Ab-01.12 Phase 1 Trial
  • Abera Bioscience secured all approvals for a Phase 1 trial of its nasal pneumococcal vaccine candidate Ab-01.12.
  • Recruitment has begun at Radboud University Medical Center in the Netherlands, targeting up to 25 healthy adults.
  • The trial will assess safety and tolerability over approximately 8-10 months, including a booster dose.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abera Bioscience AB published the original content used to generate this news brief via Cision (Ref. ID: 202611190653BITN____UKPR__SV_20261119-BIT-1602-0) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending